Covid-19:RECOVERY trial publishes preprint on dexamethasone use in ventilated patients

University of Oxford’s RECOVERY trial published its much anticipated preprint paper on the drug’s effect on Covid-19. The paper states that the drug cuts deaths in ventilated patients by one third and deaths in other admitted patients receiving oxygen by only one fifth. The headline findings of the trial were reported by the investigators on 16

Read More


Mayo Clinic finds convalescent plasma safe for diverse patients with COVID-19

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findings — from the U.S. Food and Drug Administration’s Expanded Access Program for COVID-19 — are reported in Mayo Clinic Proceedings. The safety report assessed the seven days following transfusion for hospitalized patients between April

Read More


Covid-19: are interferons helping or harming ?

The host immune system produces a variety of regulatory molecules, including interferons (IFNs), during a response to viral infection. Although previously considered beneficial, these proteins may actually cause life-threatening inflammation, according to an article published in Science on June 11. IFNs are a group of signaling proteins that are made and released by host cells in response

Read More


Individualized Treatment for COVID-19 Patients Should Be Based on Three Disease Phases

Review encourages medical personnel to develop personalized treatment based on patient’s pathophysiology A new review details three distinct phases of COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, and urges medical professionals to consider an individualized treatment approach based on the disease phases and each patient’s symptoms. The reviewis published ahead of print in Physiological Reviews.

Read More


In JAMA Patient Page an information on Convalescent Plasma and Covid-19

Donated convalescent plasma may be beneficial to patients with severecoronavirus disease 2019 (COVID-19) to boost their ability to fight the virus. What Is Convalescent Plasma?Most people who recover from COVID-19 develop antibodies (proteins that the immune system produces in response to infection) to severe acute respiratory syndrome coronavirus 2 (SARSCoV-2). Antibodies are found in plasma,

Read More


MSC Therapy for Acute Respiratory Distress Syndrome; It’s Time to Accelerate Clinical Trials for COVID-19 Patients in Need

A new systematic review and meta-analysis of clinical studies using mesenchymal stromal cells (MSCs) led by a team at the Mayo Clinic, and including researchers from Emory, Duke, Case-Western, and the University of Miami, shows a trend toward improved outcomes and reduced mortality for patients with acute respiratory distress syndrome (ARDS)—a major complication for patients with COVID-19.

Read More


Identification of genetic basis of COVID-19 susceptibility will aid treatment

The clinical presentation of COVID-19 varies from patient to patient and understanding individual genetic susceptibility to the disease is therefore vital to prognosis, prevention, and the development of new treatments. For the first time, Italian scientists have been able to identify the genetic and molecular basis of this susceptibility to infection as well as to

Read More